caa a22 4500 60615860X CHVBK 20210128100620.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s10557-015-6611-8 doi (NATIONALLICENCE)springer-10.1007/s10557-015-6611-8 Gender Differences in Cardiovascular Drugs [Elektronische Daten] [Amanda Stolarz, Nancy Rusch] The different responses of women and men to cardiovascular drugs reflect gender -specific variances in pharmacokinetic profiles and drug sensitivities coupled to inherent differences in the underlying physiology of each sex. Thus, many common cardiovascular drugs exhibit gender -specific therapeutic and adverse effects. For example, the QT interval of the electrocardiogram is longer in women compared to men, and accordingly, drugs that prolong the QT interval are more likely to cause lethal ventricular arrhythmias in female than male patients. As more clinical drug trials include women subjects, our improved knowledge base for assessing the risk/benefit ratio for cardiovascular drugs in women will enable us to consider gender as one factor in prescribing drugs and adjusting drug loading and maintenance dosages. This short review will present evidence for gender- related differences in the responses to common cardiovascular drugs including statins, antiplatelet and antithrombotic agents, β-blockers, digoxin, vasodilator therapies, and drugs associated with the Long QT Syndrome. Springer Science+Business Media New York, 2015 Cardiovascular nationallicence Drugs nationallicence Therapeutics nationallicence Medications nationallicence Gender nationallicence Side effects nationallicence Pharmacokinetics nationallicence Stolarz Amanda Department of Pharmacology and Toxicology, College of Medicine, and College of Pharmacy, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Mail Slot 611, 72205-7199, Little Rock, AR, USA aut Rusch Nancy Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham Street, Mail Slot 611, 72205-7199, Little Rock, AR, USA aut Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/4(2015-08-01), 403-410 0920-3206 29:4<403 2015 29 10557 https://doi.org/10.1007/s10557-015-6611-8 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10557-015-6611-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Stolarz Amanda Department of Pharmacology and Toxicology, College of Medicine, and College of Pharmacy, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Mail Slot 611, 72205-7199, Little Rock, AR, USA aut NATIONALLICENCE 700 1- Rusch Nancy Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham Street, Mail Slot 611, 72205-7199, Little Rock, AR, USA aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/4(2015-08-01), 403-410 0920-3206 29:4<403 2015 29 10557